Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.

Hdl Handle:
http://hdl.handle.net/10147/560596
Title:
Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.
Authors:
Else, L J; Jackson, V; Brennan, M; Back, D J; Khoo, S H; Coulter-Smith, S; Lambert, J S
Affiliation:
Rotunda Hospital Dublin
Citation:
Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy. 2014, 15 (10):604-10 HIV Med.
Journal:
HIV Medicine
Issue Date:
Nov-2014
URI:
http://hdl.handle.net/10147/560596
DOI:
10.1111/hiv.12164
PubMed ID:
24825070
Abstract:
Pregnant women experience physiological changes during pregnancy that can have a significant impact on antiretroviral pharmacokinetics. Ensuring optimal plasma concentrations of antiretrovirals is essential for maternal health and to minimize the risk of vertical transmission. Here we describe atazanavir/ritonavir (ATV/r) plasma concentrations in a cohort of pregnant women undergoing routine therapeutic drug monitoring (TDM).
Item Type:
Article
Language:
en
Keywords:
Pregnancy; Atanavir; Ritonavir
MeSH:
Adult; Analysis of Variance; Anti-HIV Agents; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pyridines; Ritonavir; Young Adult
ISSN:
1468-1293

Full metadata record

DC FieldValue Language
dc.contributor.authorElse, L Jen
dc.contributor.authorJackson, Ven
dc.contributor.authorBrennan, Men
dc.contributor.authorBack, D Jen
dc.contributor.authorKhoo, S Hen
dc.contributor.authorCoulter-Smith, Sen
dc.contributor.authorLambert, J Sen
dc.date.accessioned2015-07-17T09:26:55Zen
dc.date.available2015-07-17T09:26:55Zen
dc.date.issued2014-11en
dc.identifier.citationTherapeutic drug monitoring of atazanavir/ritonavir in pregnancy. 2014, 15 (10):604-10 HIV Med.en
dc.identifier.issn1468-1293en
dc.identifier.pmid24825070en
dc.identifier.doi10.1111/hiv.12164en
dc.identifier.urihttp://hdl.handle.net/10147/560596en
dc.description.abstractPregnant women experience physiological changes during pregnancy that can have a significant impact on antiretroviral pharmacokinetics. Ensuring optimal plasma concentrations of antiretrovirals is essential for maternal health and to minimize the risk of vertical transmission. Here we describe atazanavir/ritonavir (ATV/r) plasma concentrations in a cohort of pregnant women undergoing routine therapeutic drug monitoring (TDM).en
dc.language.isoenen
dc.rightsArchived with thanks to HIV medicineen
dc.subjectPregnancyen
dc.subjectAtanaviren
dc.subjectRitonaviren
dc.subject.meshAdulten
dc.subject.meshAnalysis of Varianceen
dc.subject.meshAnti-HIV Agentsen
dc.subject.meshDrug Monitoringen
dc.subject.meshFemaleen
dc.subject.meshHIV Infectionsen
dc.subject.meshHIV Protease Inhibitorsen
dc.subject.meshHumansen
dc.subject.meshOligopeptidesen
dc.subject.meshPregnancyen
dc.subject.meshPregnancy Complications, Infectiousen
dc.subject.meshPyridinesen
dc.subject.meshRitonaviren
dc.subject.meshYoung Adulten
dc.titleTherapeutic drug monitoring of atazanavir/ritonavir in pregnancy.en
dc.typeArticleen
dc.contributor.departmentRotunda Hospital Dublinen
dc.identifier.journalHIV Medicineen
dc.description.fundingOtheren
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.